News

Printer Friendly Version View printer-friendly version
<< Back
Array BioPharma Announces Clinical Trial Data With AZD6244 (ARRY-142886) To Be Presented at the 2006 EORTC-NCI-AACR International Meeting

BOULDER, Colo.--(BUSINESS WIRE)--Nov. 6, 2006--Array BioPharma Inc. (Nasdaq: ARRY) today announced that data from a Phase 1 trial of AZD6244 (ARRY-142886), a novel MEK inhibitor, will be presented at the 18th Annual EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics to be held from November 7-10, 2006 in Prague, Czech Republic.

Event:       EORTC-NCI-AACR Symposium on Molecular Targets and
             Cancer Therapeutics

Presenter:   Dr. Alex A. Adjei, Senior Vice-President for Clinical
             Research and Chair, Department of Medicine, Roswell Park
             Cancer Institute

Title:       Phase 1 Pharmacokinetic and Pharmacodynamic Study of the
             MEK Inhibitor AZD6244 (ARRY-142886)

Date:        Wednesday, November 8, 2006

Time:        3:00 pm CET

Location:    Prague Congress Center

About AZD6244 (ARRY-142886)

AZD6244 is a potent, selective MEK inhibitor that is orally active, that blocks signal transduction pathways implicated in cancer cell proliferation and survival. AZD6244 has shown tumour suppressive activity in multiple pre-clinical models of human cancer including melanoma, pancreatic, colon, lung, and breast cancers.

About MEK Inhibition

MEK is a critical enzyme at the intersection of several biological pathways, which regulates cell proliferation and survival as part of the Ras/Raf/MEK/ERK pathway. Activation of the Ras/Raf/MEK/ERK pathway has been implicated in many cancers, including lung, pancreatic, colon, melanoma and thyroid cancer. MEK inhibition is an attractive anti-cancer strategy as it has the potential to block inappropriate signal transduction regardless of the upstream position of the oncogenic aberration.

About Array BioPharma

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. Our proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas. For more information on Array, please go to www.arraybiopharma.com.

CONTACT: Array BioPharma Inc.
Tricia Haugeto, 303-386-1193
ir@arraybiopharma.com

SOURCE: Array BioPharma Inc.